Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Auditory neuronal cell therapy - Lineage Cell Therapeutics

X
Drug Profile

Auditory neuronal cell therapy - Lineage Cell Therapeutics

Alternative Names: ANP1; Auditory cell therapy - Lineage Cell Therapeutics; Auditory neuronal progenitor cell therapy - Lineage Cell Therapeutics; Hearing loss therapeutic - Lineage Cell Therapeutics

Latest Information Update: 28 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lineage Cell Therapeutics
  • Class Pluripotent stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hearing loss

Most Recent Events

  • 22 Mar 2023 Lineage has provisional patent application pending for ANP1 program in USA before March 2023
  • 16 Jun 2022 Preclinical trials in Hearing loss in USA (unspecified route) (Lineage Cell Therapeutics pipeline, June 2022)
  • 21 Mar 2022 Lineage Cell Therapeutics files for patent protection for composition and methods of generating auditory neuronal progenitors and methods of treatment for auditory neuropathy in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top